NONO-KO-iPSCs
CMUi002-A-1
General
Cell Line |
|
| hPSCreg name | CMUi002-A-1 |
| Cite as: | CMUi002-A-1 (RRID:CVCL_ZX41) |
| Alternative name(s) |
NONO-KO-iPSCs
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | |
| Last update | 30th July 2020 |
| User feedback | |
Provider |
|
| Generator |
Capital Medical University (CMU)
Contact:
Capital Medical University (CMU) |
| Owner | Capital Medical University (CMU) |
| Distributors | |
| Derivation country | China |
External Databases |
|
| BioSamples | SAMEA7258634 |
| Cellosaurus | CVCL_ZX41 |
| Wikidata | Q102113697 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
No |
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | Han nationality |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Family history | NO |
| Is the medical history available upon request? | NO |
| Is clinical information available? | NO |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA7002466 |
Ethics
Also have a look at the ethics information for the parental line
CMUi002-A
.
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
CMUi002-A.
|
|
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Plasmid |
| Genes | |
| Is the used vector excisable? |
No |
| Absence of reprogramming vector(s)? |
Unknown |
| Reprogramming vectors silenced? |
Yes |
| Methods used |
Immunostaining, Sequencing
|
| Notes on reprogramming vector silencing | Transfection was done using P3 Primary Cell 4D-Nucleofector® X Kit (Lonza) following the manufacturer's protocol. Transfection efficiency was observed based on GFP expression (Supplementary 1，Green light shows the expression of GFP).The puromycin selection was started 24 hours post-transfection.While the GFP-negative cells kept dying, the GFP-positive cells kept robust proliferating. |
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | The puromycin selection was started 24 hours post-transfection.While the GFP-negative cells kept dying, the GFP-positive cells kept robust proliferating.The puromycin is consistently supplied and selection is generally complete in 5–7 days. Colonies were manually picked up and seeded in 24-well culture dish and cultured until confluency. |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 5 % |
| CO2 Concentration | 5 % |
| Medium |
TeSR™ E8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Differentiation Potency
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.